Serina Therapeutics Inc. (SER)
Serina Therapeutics Statistics
Share Statistics
Serina Therapeutics has 9.93M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 9.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.62K |
| FTD / Avg. Volume | 13.2% |
Short Selling Information
The latest short interest is 31.85K, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 31.85K |
| Short % of Shares Out | 0.36% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 0.98 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Serina Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 5852.6 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Serina Therapeutics Inc. has an Enterprise Value (EV) of 18.36M.
| EV / Earnings | -1.24 |
| EV / Sales | 129.3 |
| EV / EBITDA | -1.88 |
| EV / EBIT | -1.84 |
| EV / FCF | -1.07 |
Financial Position
The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.4 |
| Quick Ratio | 2.4 |
| Debt / Equity | 0.42 |
| Total Debt / Capitalization | 29.48 |
| Cash Flow / Debt | -63.94 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is -1282.81%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | -1282.81% |
| Revenue Per Employee | $15,777.78 |
| Profits Per Employee | $-1,644,777.78 |
| Employee Count | 9 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -64.71% in the last 52 weeks. The beta is 0.86, so Serina Therapeutics's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -64.71% |
| 50-Day Moving Average | 4.68 |
| 200-Day Moving Average | 6.48 |
| Relative Strength Index (RSI) | 52.74 |
| Average Volume (20 Days) | 12.3K |
Income Statement
In the last 12 months, Serina Therapeutics had revenue of 142K and earned -14.8M in profits. Earnings per share was -1.76.
| Revenue | 142K |
| Gross Profit | -29K |
| Operating Income | -9.96M |
| Net Income | -14.8M |
| EBITDA | -9.78M |
| EBIT | -9.96M |
| Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 3.67M in cash and 268K in debt, giving a net cash position of 3.4M.
| Cash & Cash Equivalents | 3.67M |
| Total Debt | 268K |
| Net Cash | 3.4M |
| Retained Earnings | -44.32M |
| Total Assets | 6.72M |
| Working Capital | 3.31M |
Cash Flow
In the last 12 months, operating cash flow was -17.14M and capital expenditures -22K, giving a free cash flow of -17.16M.
| Operating Cash Flow | -17.14M |
| Capital Expenditures | -22K |
| Free Cash Flow | -17.16M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | -6.89K% |
| EBIT Margin | -7.01K% |
| FCF Margin | -12.08K% |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -37.05% |
| FCF Yield | -36.37% |
Analyst Forecast
The average price target for SER is $11, which is 131.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 131.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 15, 2024. It was a backward split with a ratio of 7:250.
| Last Split Date | Mar 15, 2024 |
| Split Type | backward |
| Split Ratio | 7:250 |
Scores
| Altman Z-Score | -7.24 |
| Piotroski F-Score | 3 |